Abilify
Product Images NDC 68151-5121

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 68151-5121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Chemical Structure (Abilify Chemical Structure)

Chemical structure of the active ingredient in ABILIFY by Carilion Materials Management, showing the molecular arrangement including two chlorine atoms on a benzene ring and a piperazine moiety linked to a side chain ending with an oxygen atom.*

FDA Label Image

Figure 1 (Abilify Figure 1)

A chart titled "Effect of Other Drugs on Abilify" depicting aripiprazole fold change with 90% confidence intervals. The horizontal axis shows change relative to reference (without interacting drug). Various interacting drugs are listed on the vertical axis, including CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and others. Data points with error bars illustrate the impact on aripiprazole exposure (AUC and Cmax).*

FDA Label Image

Figure 2 (Abilify Figure 2)

A plot titled 'Effect of Other Drugs on Abilify' showing the pharmacokinetic effect (AUC and Cmax) of various interacting drugs on aripiprazole. The graph presents fold change with 90% confidence intervals for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) as compared to a reference without interacting drugs.*

FDA Label Image

Figure 3 (Abilify Figure 3)

A horizontal bar chart titled 'Effect of Abilify on Other Drugs' showing fold changes and 90% confidence intervals for various drugs and enzymes, including CYP2D6, CYP2C9, omeprazole, amitriptyline, lithium, lorazepam, venlafaxine, and escitalopram, relative to reference values without the interacting drug.*

FDA Label Image

Figure 4 (Abilify Figure 4)

A horizontal bar chart displays Aripiprazole's pharmacokinetic fold changes and 90% confidence intervals across special populations including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and renal impairment, with change relative to reference on the x-axis and parameters PK, AUC, and Cmax on the y-axis.*

FDA Label Image

Figure 5 (Abilify Figure 5)

A forest plot chart depicting the fold change and 90% confidence intervals of dehydro-aripiprazole pharmacokinetics (AUC and Cmax) relative to reference groups. The variables compared include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, showing their respective effects on drug exposure.*

FDA Label Image

Figure 6 (Abilify Figure 6)

A line graph showing the proportion of subjects with relapse over days from randomization, comparing ABILIFY and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion relapsed. The graph includes numbers of subjects at risk for each group at various time points, with ABILIFY represented by a solid blue line and placebo by a dashed red line.*

FDA Label Image

Figure 7 (Abilify Figure 7)

A line graph comparing the proportion of subjects with relapse over time between ABILIFY and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes a table of the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 8 (Abilify Figure 8)

A line graph comparing the proportion of relapses over days from randomization between ABILIFY and placebo groups. The x-axis shows days from 0 to 364, and the y-axis indicates the proportion with relapse from 0 to 1. The graph includes the number of subjects at risk for both groups at various time points and a legend differentiating ABILIFY (solid blue line) and placebo (dashed red line).*

FDA Label Image

Figure 9 (Abilify Figure 9)

A line graph titled 'Change in YGTSS Total TIC Score from Baseline' showing treatment weeks on the x-axis (0 to 8 weeks) and least squares mean change in YGTSS Total TIC Score on the y-axis (0 to -20). It compares three conditions: ARIP-LOW, ARIP-HIGH, and PLACEBO, with ARIP-HIGH showing the greatest decline in score over time, ARIP-LOW intermediate decline, and PLACEBO the least change.*

FDA Label Image

Otsuka Logo (Abilify Otsuka Logo)

FDA Label Image

Label Image (Lbl681515121)

The packaging label for ABILIFY, containing aripiprazole 2 mg tablets. The label shows the manufacturer as Otsuka, lot number 3J78211, and expiration date 08/14. It includes a barcode and states 'RX ONLY.' The labeler is Carilion Materials Management, and the product NDC is 68151-5121.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.